Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo
With
The TIMI Study Group
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
21 years of age or older; male or female.
Able to provide written informed consent.
History of documented AF within the prior 12 months
A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2
You may not be if
Transient atrial fibrillation secondary to other reversible disorders
Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve
Subjects with any contraindication for anticoagulant agents;
Subjects with conditions associated with high risk of bleeding or have known or suspected hereditary or acquired bleeding disorders
Females of childbearing potential including the following:
* Females with a history of tubal-ligation
* Females less than 2 years post-menopausal
Clareo Health | Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
